Breaks Categories: News

WednesdayOct 14, 2020 11:00 am

NetworkNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data at the event hosted by the International Association for the Study of Lung Cancer. Per the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high-risk…

Continue Reading

WednesdayOct 14, 2020 10:44 am

NetworkNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Landmark Acquisition Featured in Stock2Me Podcast

SRAX (NASDAQ: SRAX), an innovative fintech solutions provider, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Christopher Miglino, founder and CEO of SRAX, and Chris Lahiji, president of LD Micro. During the program, the two executives discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced closing of the acquisition on…

Continue Reading

WednesdayOct 14, 2020 10:40 am

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary,…

Continue Reading

WednesdayOct 14, 2020 10:12 am

NetworkNewsBreaks – Exro Technologies Inc. (TSX.V: XRO) (OTCQB: EXROF) Announces Granting of Incentive Stock Options

Exro Technologies (TSX.V: XRO) (OTCQB: EXROF), a leading technology company that has developed a new class of power electronics for electric motors and powertrains, has granted incentive stock options. The options are available to specific directors, officers, employees and consultants. Qualifying individuals can purchase a total of 2,618,000 shares in the capital of the company. The shares are available at $3.15 per share, with an expiration date of five years from the date of grant. All shares sold will be pursuant to the terms of the provided stock option plan. In addition, all options will be subject to vesting provisions,…

Continue Reading

WednesdayOct 14, 2020 10:08 am

NetworkNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Enters Strategic Alliance to Build ‘Smart Factories of the Future’

Sigma Labs (NASDAQ: SGLB), a leading developer of in-process quality assurance software for the commercial 3D metal printing industry, today announced its partnership with IN4.OS, a leader in advanced manufacturing. Under the collaboration, the partners will build “Smart Factories of the Future” to meet the demands of high technology sectors including defense, space, aerospace and life sciences. An IN4.OS US LLC concept, a Smart Factory of the Future is a cyber-physical system, location agnostic factory that has the ability to deliver flexible and scalable manufacturing capabilities. The design will integrate Sigma Labs' PrintRite3D(R) technology to ensure the highest level of…

Continue Reading

TuesdayOct 13, 2020 2:04 pm

NetworkNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Bonum Health Partners with SingleCare to Enhance Enterprise Telehealth Solutions

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health-care platform, today announced that its Bonum Health subsidiary has partnered with SingleCare, the prescription savings service. According to the update, the collaboration is designed to enhance Bonum’s enterprise telehealth solutions with prescription discounts powered by SingleCare. The enterprise service will be offered to national, regional and local pharmacies to promote the benefit to underserved communities and uninsured patients. “The Bonum Health and SingleCare teams understand the importance of integrating and sustaining an affordable health-care solution at pharmacy point-of-care,” Bonum Health President Ashton Maaraba said in the news release. “We…

Continue Reading

TuesdayOct 13, 2020 1:05 pm

NetworkNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) S-4 Registration Statement Declared Effective by SEC, to Hold Special Meeting of Shareholders

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously announced the acquisition of 180 Life Sciences, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the registration statement on Form S-4 (File No. 333-234650) it filed relating to the previously announced business combination with 180 Life Sciences (the “Business Combination”). According to the update, the company has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the company’s stockholders to be held on…

Continue Reading

TuesdayOct 13, 2020 12:38 pm

NetworkNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX), Leading Cancer Charity Announce Encouraging Preliminary Phase 1 Study Results

Lineage Cell Therapeutics (NYSE American: LCTX) (TASE: LCTX) and Cancer Research UK have released encouraging results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (“NSCLC”). LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, worked together on the study, which focused on VAC2. Highlights of the study include potent induction of immune responses observed with the VAC2 vaccine and peripheral antigen-specific immunogenicity above 3% observed at multiple timepoints. In addition, VAC2 appeared to be well tolerated with…

Continue Reading

TuesdayOct 13, 2020 12:12 pm

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently,…

Continue Reading

TuesdayOct 13, 2020 11:48 am

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) Affiliate Executes $10 Million Agreement

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, has announced that its affiliate, Rail Vision Ltd., has entered into an agreement with Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX). The agreement notes that Knorr-Bremse, a multibillion-dollar European-based group, will make an investment of $10 million in Rail Vision. This follows a similar investment of $10 million made by Knorr-Bremse in 2019. With both investments in place, Knorr-Bremse will own 36.79% of Rail Vision’s outstanding share capital. In addition, Rail Vision received a call option, available when certain conditions are met,…

Continue Reading